Effects of Sonidegib Following Dose Reduction and Treatment Interruption in Patients with Advanced Basal Cell Carcinoma During 42-Month BOLT Trial

ConclusionDose reductions and interruptions were practical and did not impact the efficacy of sonidegib. In patients with advanced basal cell carcinoma who necessitate long-term treatment, dose interruptions may be beneficial for continued treatment and disease control.Trial registration: ClinicalTrials.gov identifier, NCT01327053.
Source: Dermatology and Therapy - Category: Dermatology Source Type: research